Updated Jan 27, 2020 01:44 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
C Value | A Growth | A Momentum | A VGM
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank Top 35% (88 out of 255)
Zacks Sector Rank Top 19% (3 out of 16)
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
Zacks Sector Rank Education - Learn more about the Zacks Sector Rank
The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.
Premium Research: Industry Analysis
|Top Peers||Symbol||Zacks Rank|
|ASLAN Pharmaceuticals Ltd.||ASLN|
|Alexion Pharmaceuticals, Inc.||ALXN|
|Aptose Biosciences, Inc.||APTO|
|BioDelivery Sciences International, Inc.||BDSI|
|Denali Therapeutics Inc.||DNLI|
|Kala Pharmaceuticals, Inc.||KALA|
|Oncolytics Biotech Inc.||ONCY|
Recommendations and Estimates
|Average Recommendation (1=Buy, 5=Sell)||2.13||1.37||9.99|
|Current Quarter Estimate||0.58||0.58||42.50|
|Year Ago Quarter Estimate||0.40||1.03||35.03|
|Next Quarter Estimate||0.60||0.93||40.00|
|Next Year Estimate||3.33||8.01||172.00|
|Last 5 Years||NA||19.10||7.40|
|Next 5 Years||32.00||18.50||NA|
|Price/Cash Flow (MRFY)||70.42||12.10|
|Net Profit Margin (TTM)||19.21%||-6.83%|
|Return on Equity (TTM)||20.07%||-96.49%|
|Debt to Equity (MRQ)||NA||3.52|
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.